Catastrophic antiphospholipid syndrome market seen reaching $6.8 billion by 2030

Nov. 10, 2026
Catastrophic antiphospholipid syndrome market seen reaching $6.8 billion by 2030
By AI, Created 19:00 UTC, Nov 10, 2026, AGP -

The global catastrophic antiphospholipid syndrome market is projected to rise from $4.6 billion in 2026 to $6.8 billion by 2030, according to The Business Research Company. Growth is being driven by better diagnosis, expanding treatment options, more clinical trials and higher healthcare spending, with North America leading and Asia-Pacific expected to grow fastest.

Why it matters: - Catastrophic antiphospholipid syndrome, or CAPS, is a rare autoimmune condition that can trigger rapid blood clotting and multi-organ failure. - The market outlook points to growing demand for diagnosis and treatment tools for a life-threatening disease that requires immediate intervention. - The report projects the market will keep expanding through 2030, which signals more commercial activity in rare-disease care.

What happened: - The Business Research Company released its Global Market Report 2026 on the catastrophic antiphospholipid syndrome market. - The market was valued at $4.16 billion in 2025 and is projected to reach $4.6 billion in 2026. - The report forecasts the market will climb to $6.8 billion by 2030, implying a 10.3% CAGR during the forecast period.

The details: - Improved detection of antiphospholipid antibodies is supporting market growth. - Broader use of anticoagulant therapies has helped expand treatment activity. - Better documentation of rare autoimmune disorders is increasing recognized demand. - Hospitals are expanding intensive care services that support CAPS treatment. - Plasmapheresis is being used more often in critical care settings. - The report cites complement inhibitor research, targeted biologics and precision diagnostics as major growth drivers ahead. - More clinical trials focused on rare diseases are expected to accelerate product development. - Key trends include precision immunotherapy, combination treatment regimens, early diagnosis and targeted biologic therapies. - CAPS is triggered by antiphospholipid antibodies and is typically treated with anticoagulants, corticosteroids and immunosuppressive drugs. - A growing prevalence of autoimmune diseases is a major driver behind the market's expansion. - The Crohn's and Colitis Foundation of Canada said in June 2023 that 322,600 Canadians were living with inflammatory bowel disease in 2023, with that number expected to reach 470,000 by 2035. - The same group projected annual new cases in Canada would rise from 11,000 to 14,000. - Rising healthcare spending is also boosting access to advanced diagnostics, intensive care and treatment. - The Centers for Medicare & Medicaid Services said U.S. national health expenditures rose 7.5% in 2023 to $4.9 trillion, or $14,570 per person. - Medicare spending grew 8.1% to $1,029.8 billion, equal to 21% of total national healthcare spending. - Pharmaceutical clinical trials launched in the UK increased from 411 in 2022 to 426 in 2023, according to the Association of the British Pharmaceutical Industry.

Between the lines: - The forecast reflects a rare-disease market moving from diagnosis-driven growth toward more specialized therapy development. - Stronger clinical awareness and better infrastructure are likely making previously underdiagnosed cases more visible. - The focus on biologics and precision immunotherapy suggests future competition may center on targeted, high-value therapies rather than broad supportive care alone.

What's next: - North America was the largest regional market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The Business Research Company also says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot graphics and updated trend analysis. - A free sample report is available here. - The full report is available here.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Canada Online News Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Canada Online News Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.